<DOC>
	<DOCNO>NCT02863536</DOCNO>
	<brief_summary>The POLARIS trial design multicenter , open label , non-comparative , 3 month , clinical study . Interventional , non-controlled , multicenter trial prospective design one cohort patient</brief_summary>
	<brief_title>A Study New Medical Device Polybactum®</brief_title>
	<detailed_description>To evaluate efficacy Polybactum® administer 3 cycle ( one cycle/month ) reduce rate recurrence BV woman cure vaginal metronidazole compare result treatment rate recurrence report appropriate select international literature . Therefore , Polybactum® early administration able modify basal individual risk BV recurrence .</detailed_description>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<criteria>Women 18 year . BV diagnose Amsel criterion ( see Annex 3 ) 69 day study , cure metronidazole vaginal formulation ( gel 5 day ovules 7 day ) . Diagnosis RBV ( least 2 episode BV last 12 month include BV cure baseline ) . Non lactate woman lactate non amenorrheic woman . Read sign informed consent . Pregnancy . Candidiasis mixed vaginitis . HIV immunodeficiency . Known allergy metronidazole Polybactum® ingredient . Sex worker . Menstruation premenopause/menopause . Patients concomitantly include different interventional clinical trial . Unwillingness provide informed consent trial . Time last day last menses baseline visit &gt; 16 day ≤5 day .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Recurrence Bacterial Vaginosis</keyword>
</DOC>